PureTech Health plc, a science-driven healthcare company, focuses on developing technologies that seek to address healthcare markets. The company, through its subsidiaries and operating companies, engages in developing microbiome immune system drug-discovery platform and drug candidates for the treatment of immune-mediated diseases; and products that seek to induce weight loss and potentially enhance glycaemic control through an orally administered capsule. It is also developing technology and products for the screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric di...
501 Boylston Street
Boston, MA 02116
Founded in 2015
PureTech Health plc Announces Executive Changes
Jul 8 16
PureTech Health plc announced the appointment of Feng Zhang, Ph.D. to its Scientific Advisory Board (SAB). The Company has also appointed Jeff Stevens, as Vice President of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, Dr. PH, Executive Vice President of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., Former Senior Vice President and Head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., Global Head of Diabetes Research & Development at Sanofi. Feng Zhang, Ph.D., will join PureTech as a member of the Company’s SAB. Jeff Stevens will join PureTech as Vice President of Growth Strategy & Operations. In this role, he will be helping to refine and prioritise indications and commercial opportunities for PureTech’s growth stage platforms. Mr. Stevens has been involved with the global healthcare industry for nearly 25 years. Meghan Fitzgerald, DrPH, will join PureTech as a senior advisor. She is the Executive Vice President of Strategy, M&A and Health Policy at Cardinal Health and is a member of Cardinal Health’s executive committee. She is an expert on a wide array of healthcare topics and trends, including specialty healthcare and healthcare policy. Dr. Fitzgerald leads Cardinal Health's Corporate Strategy team and previously was the President of Cardinal Health Specialty Solutions, a specialty healthcare business that offers services for healthcare providers, payers, and pharmaceutical and biotech industries. Philip J. Larsen, M.D., Ph.D., will join PureTech as a senior advisor. He is the Global Head of Diabetes R&D at Sanofi. He has 20 years of pharmaceutical and biotechnology industry experience in the field of diabetes and obesity. Previously he was Head of the Neuroendocrine Pharmacology Department at Novo Nordisk and was Chief Scientific Officer for diabetes research at Eli Lilly. Atul Pande, M.D., will join PureTech as a senior advisor. Dr. Pande has more than two decadesof experience in drug development. He has led several programmes in neurosciences, respiratory, HIV, oncology and cardiovascular therapy areas. Dr. Pande is the former Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline and has been active in the development of multiple important central nervous system drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories.
PureTech Health plc Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 09:30 AM
May 31 16
PureTech Health plc Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 09:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Daphne Zohar, Co-Founder, Chief Executive Officer and Executive Director.
PureTech Launches "Alivio Therapeutics" and Advances Novel Approach for Treating Inflammatory Disease
May 10 16
PureTech Health announced the launch of Alivio Therapeutics, which is developing a novel technology for the targeted treatment of inflammatory disorders. The technology is based on an innovative hydrogel material that is designed to adhere to and deliver drugs to inflamed tissue based on the degree of inflammation. This approach may help overcome major technical challenges in the field, enabling new therapies that have the potential to address multiple acute and chronic inflammatory disorders.